Contract Services Clinical Research
Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases,&...
October 30, 2026 | News
Ono Pharma’s ONO-1110 Shows Promising Pain Relief Signals Across Three Phase II Studies
Efficacy signals suggesting improvements in pain scores were observed in Phase 2 clinical studies in postherpetic neuralgia (PHN), fibromyalgia (FM), a...
October 30, 2026 | News
Lynk Pharmaceuticals Reports Sustained Phase III Efficacy of Zemprocitinib in Rheumatoid Arthritis Through Week 76
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...
October 29, 2026 | News
TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours
TJ-C64B is an internally developed CLDN6 × 4-1BB bispecific antibody for which TJ Biopharma retains global rights, and is among the leading pro...
October 28, 2026 | News
EU Approves Daiichi Sankyo and AstraZeneca’s Enhertu for Early HER2-Positive Breast Cancer
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive diseas...
October 28, 2026 | News
Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to...
October 27, 2026 | News
Geneos Launches Global Phase 2 Trial of Personalised Cancer Vaccine to Prevent Liver Cancer Recurrence
Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalized immunotherapy for cancer (PIC), a...
October 23, 2026 | News
Insilico Medicine Hits First AI-Driven Oncology Milestone in $888 Million Servier Collaboration
Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. Insilico reach...
October 22, 2026 | News
PharmaEssentia Accelerates Global Expansion with US and Japan Drug Approvals and US$46 Million Manufacturing Investment
PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clini...
October 21, 2026 | News
Telix and Ekalia Join Forces to Scale Astatine-211 Production for Next-Generation Cancer Therapies in the US
Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with signific...
October 20, 2026 | News
Jyong Biotech Eyes Texas Manufacturing Hub to Accelerate US Market Expansion
Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commerc...
October 19, 2026 | News
360biolabs Expands Australian Footprint with New Bioanalytical Laboratory in Sydney
The new 360biolabs facility in North Ryde is strategically located within one of Sydney’s vibrant science and medtech hubs, Macquarie Park In...
October 14, 2026 | News
Mitochondrial-Derived Peptides: What Research Has Shown So Far
Scientists have described eight MDPs: humanin, MOTS-c and six small humanin-like peptides (SHLP1 to SHLP6). Research has focused on different aspects of th...
October 12, 2026 | News
Asieris Pharmaceuticals and Theramex Sign Over $250 Million Licensing Deal for Cervical Precancer Therapy CEVIRA
Agreement is expected to grant Theramex exclusive rights to CEVIRA® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for th...
October 13, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
